Ensysce Biosciences, Inc.
ENSCWDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PF614 capsule | Phase 3 | Postoperative Pain, Acute | - | - |
PF614 | Phase 2 | Acute Pain | - | - |
Frequently asked questions
What is in Ensysce Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Ensysce Biosciences, Inc.'s (ENSCW) pipeline across Phase 3, Phase 2. Its lead program is PF614 capsule (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ensysce Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ensysce Biosciences, Inc. (ENSCW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ENSCW biotech catalysts?→
Add ENSCW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ensysce Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.